Posted by Michael Wonder on 06 Jun 2017
Bayer receives FDA approval of myBETAapp and BETACONNECT Navigator
30 May 2017 - Now-approved combination of medicine, device, mobile and cloud-based health technology.
Bayer today announced that the U.S. FDA has approved a supplemental biologics license application for myBETAapp and the BETACONNECT Navigator.
With this software in relapsing-remitting multiple sclerosis, people using the electronic BETACONNECT auto-injector to administer Betaseron (interferon beta-1b) can use Bluetooth technology to connect their current auto-injector to the new myBETAapp on their mobile device or computer.
Patients have the opportunity to share their injection data with their BETA Nurse and health care team. Viewing this data through the BETACONNECT Navigator may be a useful tool for the health care team to gain insights into patients' injection history and provide support to those taking Betaseron.
